CTOs on the Move


 
Your partner in ELEVATING SCIENCE.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.bioivt.com
  • 770, PO Box
    Hicksville, NY USA 11802
  • Phone: 516.483.1196

Executives

Name Title Contact Details

Similar Companies

Canadian Innovation Centre

Canadian Innovation Centre is a Port Elgin, ON-based company in the Business Services sector.

Hintzsche Feeds

As an honest and trustworthy family-owned company, we are committed to establishing and maintaining long-term and beneficial partnerships with our customers and employees. Hintzsche provides innovative products, information and services to the

EDAL INDUSTRIES

EDAL INDUSTRIES INCORPORATED is a East Haven, CT-based company in the Business Services sector.

Linda L. Schwichtenberg, P.A.

Linda L. Schwichtenberg, P.A. is a Orlando, FL-based company in the Business Services sector.

enGene

At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN